These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26726089)

  • 1. Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate.
    Narukawa K; Kakihana K; Fujiwara T; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Intern Med; 2016; 55(1):69-72. PubMed ID: 26726089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia.
    Ong J; Yeung D; Filshie R; Hughes TP; Nandurkar H
    Int J Hematol; 2015 Nov; 102(5):639-42. PubMed ID: 26134364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review.
    Abu-Amna M; Awadie H; Bar-Sela G
    Anticancer Res; 2016 Nov; 36(11):6151-6154. PubMed ID: 27793944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Watermelon stomach: Chronic renal failure and/or imatinib?].
    Montagnac R; Blaison D; Brahimi S; Schendel A; Levasseur T; Takin R
    Nephrol Ther; 2015 Nov; 11(6):496-501. PubMed ID: 26165799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Imatinib-induced gastric antral vascular ectasia" in a reporting system of the Japanese Adverse Drug Event Report database.
    Oshima Y; Yuji K; Tojo A
    Int J Hematol; 2016 May; 103(5):596-8. PubMed ID: 26980219
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
    Saad Aldin E; Mourad F; Tfayli A
    Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
    Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
    J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
    Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
    Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
    Faber E; Nausová J; Jarosová M; Egorin MJ; Holzerová M; Rozmanová S; Maresová I; Divoký V; Indrák K
    Leuk Lymphoma; 2006 Jun; 47(6):1082-90. PubMed ID: 16840200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
    Wetzler M; Donohue KA; Odenike OM; Feldman EJ; Hurd DD; Stone RM; Westerfelt P; Bloomfield CD; Larson RA
    Leuk Lymphoma; 2008 Jul; 49(7):1274-8. PubMed ID: 18452072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
    Singh S; Sharma PK
    Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
    Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
    Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
    Miyashita K; Fujimaki K; Ishigatsubo Y
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):405-7. PubMed ID: 23507609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 19. Conjunctival hemorrhagic events associated with imatinib mesylate.
    Radaelli F; Vener C; Ripamonti F; Iurlo A; Colombi M; Artoni A; Reda G; Deliliers GL
    Int J Hematol; 2007 Dec; 86(5):390-3. PubMed ID: 18192104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
    Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
    Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.